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We identified a mutation in the Diet1 gene in a mouse
strain that is resistant to hyperlipidemia and athero-
sclerosis. Diet1 encodes a 236 kD protein consisting
of tandem low-density lipoprotein receptor andMAM
(meprin-A5-protein tyrosine phosphatase mu) do-
mains and is expressed in the enterocytes of the
small intestine. Diet1-deficient mice exhibited an
elevated bile acid pool size and impaired feedback
regulation of hepatic Cyp7a1, which encodes the
rate-limiting enzyme in bile acid synthesis. In mouse
intestine and in cultured human intestinal cells, Diet1
expression levels influenced the production of fibro-
blast growth factor 15/19 (FGF15/19), a hormone that
signals from the intestine to liver to regulate Cyp7a1.
Transgenic expression of Diet1, or adenoviral-medi-
ated Fgf15 expression, restored normal Cyp7a1
regulation in Diet-1-deficient mice. Diet1 and FGF19
proteins exhibited overlapping subcellular localiza-
tion in cultured intestinal cells. These results estab-
lish Diet1 as a control point in enterohepatic bile
acid signaling and lipid homeostasis.
INTRODUCTION
Impaired regulation of bile acid production and cholesterol
excretion are underlying factors in the pathogenesis of several
common clinical conditions, such as hypercholesterolemia, car-
diovascular disease, bile acid malabsorption, gallstone disease,
and type 2 diabetes (Angelin et al., 1999; Goldfine, 2008; Hage-
man et al., 2010; Khurana et al., 2011; Thomas et al., 2008; Wal-
ters and Pattni, 2010). Bile acids are synthesized from choles-
terol in the liver in a highly regulated manner, stored in the gall
bladder, and secreted into the duodenum in response to a
meal (Hofmann, 2009; Hylemon et al., 2009; Lefebvre et al.,
2009; Russell, 2003, 2009). Bile acids play a critical role in the ab-
sorption of dietary fats and fat-soluble vitamins in the upper
small intestine, prior to reabsorption of approximately 95% of
bile acids in the ileum. The remaining 5% of bile acids are916 Cell Metabolism 17, 916–928, June 4, 2013 ª2013 Elsevier Inc.excreted, providing a means for sterol elimination from the
body. Prior to the availability of statin drugs for the treatment
of hypercholesterolemia, the use of bile acid sequestrants was
a common strategy to lower cholesterol levels (Angelin et al.,
1999). Bile acid sequestration leads to reduced bile acid reab-
sorption, increased conversion of cholesterol to bile acids in
the liver, increased LDL receptor expression, and reduced lipo-
protein cholesterol levels. In recent years, bile acid sequestrants
have reemerged as a potential treatment paradigm for condi-
tions ranging from bile acid malabsorption to type 2 diabetes
(Aggarwal et al., 2012; Goldfine, 2008; Handelsman, 2011;
Thomas et al., 2008; Westergaard, 2007).
Also in recent years there has been a leap forward in our
understanding of the regulation of bile acid homeostasis. An intri-
cate mechanism exists for feedback regulation of bile acid syn-
thesis involving communication from the small intestine to the
liver via fibroblast growth factor 15 (FGF15) in mouse, or
FGF19 in humans (reviewed in Cicione et al., 2012; Jones,
2012; Potthoff et al., 2011). In the small intestine, bile acids acti-
vate the farnesoid X receptor (FXR) to promote Fgf15/FGF19
gene transcription and protein secretion into the enterohepatic
circulation. Upon reaching the liver, FGF15/19 interacts with
the FGF receptor 4/b-klotho complex and leads to transcrip-
tional repression of the Cyp7a1 gene, which encodes the rate-
limiting enzyme for the classic pathway of bile acid synthesis
(Inagaki et al., 2005; Kim et al., 2007; Lunda˚sen et al., 2006). A
recent study has shown that conditions characterized by bile
acid malabsorption in humans are often associated with
decreased FGF19 levels, suggesting that increased bile acid
synthesis, rather than impaired absorption, is the likely culprit
(Walters et al., 2009). Thus, an understanding of factors that
regulate FGF15/19 levels is of interest. In addition to FXR, vita-
mins A and D regulate Fgf15 gene transcription through the ac-
tion of vitamin D and retinoid-responsive nuclear receptors
(Schmidt et al., 2010). It is unknown whether additional control
points for FGF15/19 production operate.
Several years ago, Lusis and colleagues identified a substrain
of C57BL/6 mice, C57BL/6ByJ, which had low circulating lipid
levels and resistance to atherosclerosis (Mouzeyan et al.,
2000). This was notable because the C57BL/6J mouse strain
from which the substrain was derived is highly susceptible to
hypercholesterolemia and atherosclerosis. We found that the
resistance to hypercholesterolemia in C57BL/6ByJ mice was
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(2-fold) and urine (18-fold) (Phan et al., 2002). In a genetic cross,
the reduced plasma cholesterol levels and elevated bile acid
levels cosegregated, indicating that a single genetic locus was
responsible for controlling both (Phan et al., 2002). We hypoth-
esized that a mutation had occurred in C57BL/6ByJ mice that
led to dysregulated bile acid metabolism. Here we report the
identification of the responsible mutation in a previously unchar-
acterized gene, Diet1, and demonstrate that Diet1 has a role in
the FGF15/19 intestine-liver axis for the regulation of bile acid
synthesis.
RESULTS
Identification of the Diet1 Gene and Null Mutation in
C57BL/6ByJ Mice
The Diet1 locus was previously mapped to a 20 cM region on
proximal chromosome 2 (Mouzeyan et al., 2000). To map the
gene to high resolution, we generated a backcross between
C57BL/6ByJ (B6By) and CAST/EiJ mice and typed bile acid
levels in 790 offspring to narrow the Diet1 locus to a region of
approximately 11 Mb, between markers D2Mit359 and D2Mit6.
Mice that were homozygous for the B6By allele throughout this
region exhibited high serum bile acid levels (>30 mM), whereas
heterozygous mice exhibited low bile acid levels (<10 mM).
Mice with recombination events within this interval were used
to further narrow the Diet1 locus. To confirm correspondence
between bile acid levels and genotype, we subjected recombi-
nant mice to progeny testing by backcrossing to B6By mice.
At least 20 backcross offspring from each recombinant were
subsequently typed for bile acid levels and genetic markers.
This analysis narrowed the Diet1mutation to a 2.4 Mb region be-
tweenD2Mit360 andD2Mit267 (Figure 1A and Table S1 available
online). This region harbors four known genes and a few small
predicted genes, which we later found comprise a single gene
that was not annotated in the genome sequence (see below).
The four known genes in the Diet1 gene critical interval
showed normal messenger RNA (mRNA) expression levels in
B6By mouse tissues (Figure S1). However, analysis of the pre-
dicted gene sequence showed prominent expression of a 7 kb
mRNA in the small intestine of control C57BL/6J (B6J) mice
that was absent in B6By mice fed either chow or atherogenic
diets (Figure 1B). We used a combination of genome sequence
information and 50 and 30 RACE (rapid amplification of comple-
mentary DNA [cDNA] ends) to isolate a full-length 6963 bp
cDNA from B6J intestinal RNA. Mapping of the cDNA sequence
to the mouse genome revealed that the Diet1 gene spans
approximately 730 kb and comprises 39 exons (Figure 1D, top
line). To identify the mutation present in the B6By genome, we
sequenced each of the 39 exons and all intron/exon junctions,
but we found no differences in B6By compared to the wild-
type B6J. However, using portions of the Diet1 cDNA to probe
genomic Southern blots, we found that a probe corresponding
to exon 23 of theDiet1 gene produced an abnormal hybridization
patternwith B6ByDNA (Figure 1C). Extra bandswere detected in
digests with different restriction enzymes, suggesting that dupli-
cation of a portion of the Diet1 gene has occurred in the B6By
genome. Sequence analysis revealed that the B6By genome
contains a duplication of exons 21, 22, and 23 (Figure 1D). TheCinclusion of these inserted exons in theDiet1mRNA transcript in-
troduces a frame shift and premature stop codon (Figure 1D,
lower line), presumably resulting in nonsense-mediated mRNA
decay and accounting for the absence of detectable Diet1
mRNA by northern blot (Figure 1B).
Diet1 Is an Evolutionarily Conserved Modular Protein
Mouse Diet1 encodes a protein of 2,123 amino acids and a pre-
dicted molecular weight of 236 kD. Analysis of the protein
sequence revealed several known protein domains (Figure 1E).
Accounting for a large portion of the protein are nine copies of
the MAM (meprin-A5-protein tyrosine phosphatase mu) domain,
a 170 amino acid domain that contains four conserved cysteine
residues that likely form two disulfide bridges (Beckmann and
Bork, 1993). The MAM domain is a component of numerous pro-
teins with diverse functions and has been implicated in protein-
protein interactions, signal transduction, and cell-cell adhesion
(Cismasiu et al., 2004; Ishmael et al., 2005). Also present in
Diet1 are nine low-density lipoprotein (LDL) receptor (class A)
domains, an epidermal growth factor-like (subtype 2) domain,
and a putative transmembrane domain near the C terminus (Fig-
ure 1E). LDL receptor domains are approximately 40 amino acids
in length and contain six disulfide-bound cysteines and a highly
conserved cluster of negatively charged amino acids, which
affect LDL receptor binding to its apolipoprotein ligands (Yama-
moto and Ryan, 2009).
We sequenced Diet1 cDNA from intestinal mRNA of additional
species, including human, rat, chicken, frog, and zebrafish. The
predicted Diet1 protein sequences are highly conserved with a
nearly identical MAM-LDL receptor domain organization (Fig-
ure 1E). The human DIET1 gene spans 686 kb on chromosome
10p12 and encodes a predicted protein of 2,156 amino acids
that is 70% identical to mouse Diet1. On the basis of both the
experimentally determined cDNA and genomic DNA sequences,
the zebrafish protein appears to be truncated at the amino-termi-
nal end relative to the other species. We could not identify Diet1
orthologs in invertebrates or lower organisms. Of known pro-
teins, Diet1 had significant similarity to endotubin (also known
as apical early endosomal glycoprotein), a 140 kD membrane
glycoprotein containing five MAM and two LDL receptor do-
mains (Allen et al., 1998; Gokay et al., 2001; Wilson and Colton,
1997). Endotubin regulates trafficking of tight junction proteins in
polarized epithelial cells (McCarter et al., 2010).
Diet1 Is Expressed in Intestinal Epithelial Cells
To begin to understand its physiological function, we character-
ized the tissue distribution and developmental profile of Diet1
expression. In situ hybridization to cross-sections through an
adult mouse indicated that Diet1 expression is limited to the
small intestine and kidney cortex and is not detected in other tis-
sues, including liver (Figure 2A). In situ hybridization of mouse
embryos failed to detect expression during midgestation (at
9.5, 12.5, and 14.5 days postconception [dpc]) but detected
Diet1 mRNA in the intestinal primordium at 15.5 dpc and
increasing expression levels through postnatal days 1 and 10, at-
taining a maximal level in adulthood (Figure S2). Gene expres-
sion analysis by RT-PCR in tissue panels frommouse (Figure 2B)
and human (Figure 2C) confirmed that Diet1 is expressed pre-
dominantly in the small intestine, with low-level expression alsoell Metabolism 17, 916–928, June 4, 2013 ª2013 Elsevier Inc. 917
Figure 1. Identification of the Diet1 Gene Mutation in C57BL/6ByJ Mice by Positional Cloning
(A) Localization of the Diet1 gene on mouse chromosome 2 by mapping in a C57BL/6ByJ (B6By) 3 CAST/EiJ backcross. The delimiting DNA microsatellite
markers and known genes in the interval are listed. The gene labeled ‘‘Unknown’’ was a collection of several predicted genes that we determined by sequencing
to belong to a single Diet1 mRNA transcript.
(B) Northern blots showing Diet1 mRNA expression in the small intestine of C57BL/6J (B6J) but not B6By mice. Diet1 expression levels are similar in C57BL/6J
mice fed chow and atherogenic (Ath) diets after normalization to hypoxanthine phosphoribosyltransferase (Hprt). Diet1 mRNA migrates between RNA ladder
markers sized 6.6–9 kb.
(C) Southern blot of B6J and B6By genomic DNA probed with exon 23 of the Diet1 gene. Duplication of part of the gene is evident as extra bands detectable in
B6By samples (arrows) upon digestion with ApaLI, BamHI, and EcoRI.
(D) Top: Genomic structure of the wild-type mouse Diet1 gene. Vertical bars represent exons. Middle: Duplication of exons 21–23 in the B6By mutant allele.
Sequence analysis positioned the duplicated region 15 kb downstream of exon 20. The inset illustrates detection exclusively in B6By mice of a PCR product
generated with primers spanning the 30 boundary of the duplicated region (primers mDiet1 dup, Supplemental Experimental Procedures). Bottom: Black shading
indicates the altered amino acid sequence and premature stop codon (denoted by asterisk) that result from mutation in B6By mice. The normal sequence in
C57BL/6J mice is shown above for comparison.
(E) Predicted functional motifs in Diet1 protein from the species indicated; the predicted number of amino acids is shown at right. Functional domains were
predicted by Prosite. MAM,meprin-A5-protein tyrosine phosphatase mu; LDLR A2, low-density lipoprotein receptor A2motif; EGF, epidermal growth factor. The
gray bar represents a predicted transmembrane domain.
See also Figure S1 and Table S1.
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mRNA levels increased along the length of the small intestine
from duodenum to ileum and were not detected in stomach or918 Cell Metabolism 17, 916–928, June 4, 2013 ª2013 Elsevier Inc.colon (Figures 2D and S3). High-resolution in situ hybridization
revealed that Diet1 expression was localized to the villi in the in-
testinal lumen, and the signal was present in the epithelial cell
Figure 2. Diet1 Expression in Enterocytes of the Small Intestine
(A) In situ RNA hybridization analysis ofDiet1 expression in adult whole mouse sections. Images at the top show sections stained with hematoxylin and eosin, and
images at the bottom show the in situ hybridization signals. J, jejunum; I, ileum; K, kidney; Cx, renal cortex; Me, renal medulla.
(B) Diet1 mRNA expression in a mouse tissue panel determined by RT-PCR. Corresponding Hprt expression levels are shown. S. Intestine, small intestine.
(C) qPCR analysis of DIET1 mRNA in pooled human tissue samples and normalized to HPRT and b2-microglobulin expression.
(D) qPCR quantitation of Diet1 mRNA in mouse gastrointestinal tract. n = 3 (mean ± SD). Sto, stomach; Duo, duodenum; Jej, jejunum; Ile, ileum; Col, colon.
(E) High-resolution in situ image from small intestine shows Diet1 mRNA (light granules) concentrated in epithelial cells along the surface of villi (V).
(F) Induction of endogenous DIET1mRNA expression during differentiation of the Caco-2 human intestinal cell line. The expression of sucrase isomaltase (SI) is
shown as a positive control for differentiation. qPCR values were normalized to HPRT and b2-microglobulin. n = 3 (mean ± SD).
(G) Diet1 protein visualized in mouse intestinal enterocytes by immunofluorescent confocal microscopy. Intestine from a mouse strain expressing a V5-epitope
tagged Diet1 transgene was stained with antibodies against Diet1-V5 (green). The apical membrane was detected with antibody against the apical salt-
dependent bile acid transporter (ASBT, red), and nuclei were stained with DAPI (blue).
(H) Enlargement of boxed region in (G) shows complete lack of colocalization between Diet1 and ASBT.
See also Figures S2 and S3.
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serosa (Figures 2E and S3).
To assess whether Diet1 expression is regulated during intes-
tinal epithelial cell development, we utilized the human Caco-2
cell line, which differentiates in vitro to acquire properties of small
intestine epithelial cells, including expression of the brush border
microvilli and enzymes, formation of tight junctions, and a variety
of transport functions (Rousset et al., 1985). DIET1 mRNA
expression was very low in undifferentiated cells and was
induced 120-fold during Caco-2 cell differentiation, in concert
with the expression of sucrose isomaltase (Figure 2F). These ob-
servations suggest that Diet1 functions primarily in mature intes-
tinal epithelial cells.
To investigate the subcellular localization of Diet1 protein, we
performed immunofluorescence confocal microscopy onmouse
ileum sections. To ensure specific detection of Diet1 without
cross-reactivity to other endogenous proteins, we generated
C57BL/6J mice expressing a Diet1 cDNA with a carboxyl-termi-
nal V5 epitope tag under control of the ileal fatty acid binding pro-
tein (IFABP) regulatory elements (Cohn et al., 1992). As dictated
by the IFABP promoter, Diet1-V5 protein was expressed in en-
terocytes lining the villi. Diet1-V5 protein appeared in a punctate
distribution within the cytosol and was not present in the apical
enterocyte membrane, as determined by lack of colocalization
with the ileal apical sodium-dependent bile acid transporter
(ASBT, also known as Slc10a2) (Figures 2G and 2H). These
observations suggest that the predicted membrane-spanning
region of the protein is associated with themembrane of an intra-
cellular compartment, although we cannot rule out the possibility
that Diet1 transiently cycles to the cell membrane.
Diet1 Deficiency Reduces Ileal FGF15 Levels and
Impairs the Regulation of Hepatic Bile Acid Metabolism
Genes
We previously observed that B6By mice exhibit elevated plasma
bile acid levels and enhanced bile acid excretion compared
to C57BL/6J mice (Phan et al., 2002). Analysis of bile acids
in blood and tissues by gas chromatography/mass spectrometry
revealed an expanded bile acid pool size in B6By mice in the
circulation, liver, and gastrointestinal tract (duodenum, jejunum,
ileum, and gall bladder) (Figure 3A). Elevations were observed
across bile acid species, with the most notable increase occur-
ring in cholic acid levels and in the form of tauro-conjugated
bile acids (Figure 3B).
Consistent with the increased bile acid pool size, B6By mice
had elevated expression of genes involved in bile acid synthesis
in the liver, including Cyp7a1 and Cyp27 (Figure 3C; Phan et al.,
2002). We also detected enhanced hepatic expression of genes
for the bile salt export pump (Abcb11) and the liver receptor ho-
molog-1 nuclear receptor (Nr5a2), which modulates Cyp7a1
expression levels (Figure 3C).
Since Diet1 expression is not detectable in liver (Figure 2), it
was unclear how Diet1 deficiency influences hepatic gene
expression and bile acid levels. One possibility was that Diet1-
deficient mice have reduced bile acid uptake in the ileum, lead-
ing to increased bile acid excretion and a compensatory
increase in bile acid production in the liver. Bile acid uptake in
the ileum is governed by ASBT, which is encoded by Slc10a2
(Dawson et al., 2009). Both mRNA levels and protein levels for920 Cell Metabolism 17, 916–928, June 4, 2013 ª2013 Elsevier Inc.ASBT were normal or elevated in B6By compared to C57BL/
6J mice (Figures 3D and 3E). Furthermore, ASBT protein was
visible on the apical membrane of ileum in B6By mice (Figures
3F and 3G). Thus, the elevated bile acid levels in B6By mice
appear not to result from defective ASBT production or
localization.
We searched for another mechanism that could explain the
elevated bile acid levels and the persistence of high bile acid
biosynthetic gene expression in liver of Diet1-deficient mice.
B6By mice had normal intestinal mRNA levels for the Osta and
Ostb bile acid transporters located on the basolateral surface
of the enterocytes, intestinal bile acid binding protein (Fabp6),
nuclear receptors FXRa (Nr1h4) and LXRa (Nr1h3), and the short
heterodimeric partner (Nr0b2) (Figure 3D). However, we de-
tected significantly reduced mRNA levels for fibroblast growth
factor 15 (Fgf15) (Figure 3D), a hormone that is synthesized in
the ileum and signals through the enterohepatic circulation to
downregulate Cyp7a1 expression in the liver (Inagaki et al.,
2005; Jones, 2008). FGF15 protein levels in the ileum of B6By
mice were also decreased compared to C57BL/6J mice (Fig-
ure 3H). The expression of fibroblast growth factor receptor 4
(Fgfr4), which functions with b-klotho (Klb) as a coreceptor for
FGF15 on the hepatocyte surface, was elevated 2-fold in B6By
liver (Figure 3C). On the basis of our results, we hypothesized
that Diet1 influences FGF15 production in the intestine, leading
to downstream effects on the regulation of hepatic Cyp7a1
expression.
Diet1 Levels Influence Fgf15 and Cyp7a1 Expression
In Vivo
To test our hypothesis, we assessed whether increasing the
levels of Diet1 in vivo leads to enhanced Fgf15 expression and
reduced Cyp7a1 expression. As described above, we generated
C57BL/6J mice that express a Diet1-V5 transgene in small
intestine. Transgene expression was detectable in intestine via
quantitative PCR (qPCR) with transgene-specific PCR primers
(Figure S4A). However, the transgene expression levels were
low compared to endogenous Diet1 expression levels, and
therefore they did not significantly increase the total levels of
Diet1 mRNA in the wild-type C57BL/6J strain background (Fig-
ure S4A). Therefore, we could not use this mouse model to
assess the consequences of Diet1 overexpression. However,
the Diet1 transgenic strain was valuable for complementation
of Diet1 deficiency in B6By mice.
Introduction of the Diet1 transgene into the B6By strain
increased Diet1 mRNA expression to detectable levels (Fig-
ure 4A). The Diet1 transgene expression levels differed between
sexes, with female transgenics (Figure 4A) expressing higher
Diet1 mRNA levels than males (Figure S4B). Compared to
B6By mice, B6By + Diet1 transgenic mice had significantly
higher Fgf15 mRNA levels and a trend to reduced Cyp7a1
mRNA levels (Figures 4A and S4B). An analysis of expression
levels in all of the male and female mice revealed highly signifi-
cant positive correlations between Diet1 and Fgf15 expression
levels, as well as inverse correlations between Diet1 and
Cyp7a1 expression levels and Fgf15 and Cyp7a1 expression
levels (Figure 4B). Thus, changes in Diet1 expression levels
lead to correlative increases in Fgf15 mRNA levels and inverse
effects on Cyp7a1 expression levels.
Figure 3. Diet1-Deficient Mice Have Increased Bile Acid Pool Size and Reduced Ileal FGF15 mRNA and Protein Levels
(A) Bile acid content is increased in plasma, liver, and gall bladder (GB) plus small intestine of Diet1-deficient B6By compared to B6J mice. After 3 weeks on an
atherogenic diet, mice were fasted 16 hr, tissues were collected, and bile acid concentrations were determined by high-performance liquid chromatography
followed by enzymatic reaction and fluorescence detection. n = 6 (mean ± SD). *p < 0.05.
(B) Bile acid composition in plasma of B6J and B6Bymice from (A). Left, concentration of bile acid species; right, conjugation status of bile acids. CA, cholic acid;
MCA, muricholic acid; DCA, deoxycholic acid, CDCA, chenodeoxycholic acid; UDCA, ursodeoxycholic acid. n = 6 (mean ± SD). *p < 0.05.
(C and D) Relative gene expression levels in liver (C) and small intestine (D) of B6J and B6Bymice determined by qPCR. Values are expressed as the ratio of levels
in B6By compared to B6J mice. Black bars indicate genes with similar expression levels in B6By and B6J. Blue bars indicate genes with elevated expression in
B6By mice, and the red bar indicates the gene with reduced expression in B6By mice compared to B6J mice. See the main text for full gene names. n = 4
(mean ± SD). *p < 0.05 in B6By versus B6J.
(E) Western blot analysis of ASBT in ileum of B6J and B6By mice. b-actin is shown as a loading control from a different region of the same gel lanes.
(F) ASBT protein visualized in B6By mouse intestinal enterocytes via immunofluorescent confocal microscopy. ASBT is stained red, and DNA is stained blue
with DAPI.
(G) Enlarged inset from (F).
(H) FGF15 protein quantification in B6J and B6By mouse ileum by ELISA. Validation of the specificity of this ELISA is shown in Figure S5. n = 9–10 (mean ± SD).
*p < 0.05.
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Cyp7a1 in Diet1-deficient mice results from reduced FGF15
levels, we restored FGF15 expression in B6By mice by adeno-Cvirus-mediated FGF15 expression. Mice were administered re-
combinant adenovirus expressing FGF15 (Inagaki et al., 2005)
or lacZ, and tissues were collected 6 days later. Infection withell Metabolism 17, 916–928, June 4, 2013 ª2013 Elsevier Inc. 921
Figure 4. In Vivo Correlation betweenDiet1,
Fgf15, and Cyp7a1 Expression, and Cyp7a1
Normalization by Adenovirus-Mediated
Fgf15 Expression in Diet1-Deficient Mice
(A) qPCRanalysis of intestinalDiet1 andFgf15, and
hepatic Cyp7a1 mRNA levels in female B6By and
B6By+Diet1-Tgmice. Shownarebox-and-whisker
plots with medians, quartiles (boxes), and minima
and maxima (lines) indicated. n = 5 (B6By) and 6
(B6By+Diet1-Tg). Statistical significance was
determined by Mann-Whitney U test. **p < 0.01.
(B) Correlations between intestinal Diet1, intestinal
Fgf15, and hepatic Cyp7a1 mRNA levels in indi-
vidual B6By and B6By+Diet1-Tg mice. Log-
transformed (Ln) mRNA levels were used. n = 24.
(C) Adenoviral-mediated expression of FGF15 in
Diet1-deficient mice for 6 days influenced Cyp7a1
mRNA, fasting glucose, and glucose-6-phospha-
tase (G6p) mRNA levels. n = 5 (mean ± SD). *p <
0.05 versus adenoviral-mediated lacZ (AdLacZ)
expression.
See also Figure S4.
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expression in B6By mouse liver (Figure 4C). In addition to bile
acid synthesis, FGF15 inhibits hepatic glucose production
(Potthoff et al., 2011). Consistent with this, administration of
FGF15 also reduced the fasting glucose levels observed in
B6By mice, and this was reflected in reduced expression of
glucose-6 phosphatase (Figure 4C). These findings indicate
that the defect in bile acid feedback regulation in B6By mice is
reduced availability of FGF15 and that the signaling pathway
downstream of FGF15 is not impaired in B6By mice.
Diet1 Modulates Levels of FGF19 Secreted from
Cultured Intestinal Cells
To investigate whether Diet1 levels acutely influence FGF15 pro-
duction in intestinal cells, we modulated Diet1 levels in cultured
intestinal cells. The most well-established intestinal cell lines are
of human origin, and we screened three cell lines for expression
and secretion of FGF19, the human ortholog of mouse FGF15. Of
three human intestinal cell lines (HT-29, Caco-2, and COLO 205)
(Semple et al., 1978; Zweibaum et al., 1983), HT-29 cells ex-
pressed and secreted FGF19 most robustly, and we therefore
selected these cells for our studies. We investigated whether
acute alterations in Diet1 expression levels influence levels of
FGF19 mRNA expression and FGF19 protein secreted into the922 Cell Metabolism 17, 916–928, June 4, 2013 ª2013 Elsevier Inc.medium. HT-29 cells transfected with a
Diet1 expression vector increased
FGF19 mRNA levels slightly (30%) and
increased FGF19 protein secretion into
the culture medium by 3-fold (left panels
in Figures 5A–5C). In the complementary
experiment, a 60% knockdown in Diet1
mRNA levels did not affect FGF19
mRNA expression but reduced FGF19
levels in the culture medium by 40% (right
panels in Figures 5A–5C). The secretion
of apolipoprotein A-I was not affected
by modulating Diet1 levels (Figure 5D),indicating that the effects on FGF19 results are not due to a
nonspecific effect on secreted proteins.
Our results indicated that Diet1 has a modest effect on FGF19
mRNA levels and a pronounced effect on FGF19 protein levels,
but did not distinguish whether the protein levels increase sec-
ondary to mRNA levels or are also influenced by Diet1 at the
posttranscriptional level. To investigate whether Diet1 influences
FGF19 protein levels in a transcription-independent manner, we
expressed FGF19 under the control of a heterologous promoter
that should be transcribed at a constitutive level. The expression
of increasing amounts of Diet1 led to increased levels of cellular
and secreted FGF19 protein (Figures 5E and 5F). These results
indicate that Diet1 has an effect on FGF19 protein production
that is independent of an effect on FGF19 mRNA levels. Taken
together, our results from in vivo and in vitro systems indicate
that Diet1 influences FGF15/FGF19 levels at both the mRNA
and posttranscriptional levels.
Diet1 Colocalizes with and Interacts with FGF15
As described above, Diet1 influences FGF19 levels, in part,
throughaposttranscriptionalmechanism. To further characterize
the relationshipbetweenDiet1 andFGF15proteins,weexamined
their subcellular localization in intestinal cells. For these studies,
we used the IEC-6 rat intestinal cell line (Quaroni et al., 1979)
Figure 5. Diet1 Levels Influence FGF19 Pro-
duction at Both the mRNA and Posttran-
scriptional Levels
(A) Human DIET1 expression levels in the human
HT-29 intestinal cell line were increased several
fold by transfection with human DIET1 cDNA (left)
or reduced 60% by knockdown with DIET1 small
interfering RNA (siRNA; right). Levels of expression
were compared to control cells treated with empty
plasmid vector (Vec.) or scrambled siRNA (Scr.).
(B) FGF19 mRNA levels from cells in (A). DIET1
overexpression modestly increased FGF19
mRNA, whereas DIET1 knockdown did not alter
FGF19 expression.
(C) FGF19 protein secreted into the medium of
cells in (A). FGF19 protein levels increased 3-fold
with DIET1 overexpression and decreased 40%
with partial DIET1 knockdown.
(D) ApoAI protein secreted into the culture medium
of cells in (A). Levels were unaltered by DIET1
overexpression or knockdown.
(A–D) Values represent mean ± SD for three repli-
cates. *p < 0.05 versus Vec. or Scr. controls.
(E) Diet1 influences FGF19 protein levels, in part, at
theposttranscriptional level. FGF19wasexpressed
under control of a heterologous promoter in the
absence of Diet1 (empty vector control) or pres-
ence of increasing amounts (13 and 43) of Diet1
expression vector. Cellular and secreted proteins
were detected by western blot. b-actin protein
levels were unaffected by Diet1, whereas FGF19
protein increased with higher levels of Diet1.
(F) Quantification of intracellular and secreted
FGF19 from (E) after normalization to b-actin. n = 4
(mean ± SD). *p < 0.05 versus empty vector control;
#p<0.05versusemptyvectorand13Diet1 sample.
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Diet1 in the Enterohepatic Signaling Axisbecause it allows better visualization of proteins in the cytoplasm
than human cell lines that we tested (Caco-2, HT-29, or COLO
205). As we observed in mouse intestine (Figure 2G), Diet1 was
present in a punctate cytosolic pattern (Figure 6A). FGF15 also
appeared in a punctate cytosolic distribution, and there
appeared to be substantial overlap between Diet1 and FGF15
(yellow signal in Figures 6A and 6B). A proportion of Diet1 and
FGF15 colocalized in structures having a vesicle-like appearance
(Figure 6B, arrowheads). This suggested that Diet1 might be
present in an endosomal/lysosomal trafficking compartment,
and we sought to colocalize Diet1 with established vesicular
trafficking markers. We could not detect any colocalization of
Diet1 with markers of early endosomes (EEA1 and Rab5), late
endosomes (Rab7), or lysosomes (LimpII) (Figure 6C). Thus,
Diet1 and FGF15 may reside in a distinct vesicular subtype.
The close proximity of Diet1 and FGF15 within the cell raised
the possibility that the two proteins physically interact. Immuno-
precipitation directly from mouse intestine was not possible as
our antibodies detected several nonspecific bands in this tissue
(data not shown). We therefore expressed human Diet1-V5- and
FGF19-Myc-tagged proteins in human HEK293 cells and as-
sessed whether the two proteins coimmunoprecipitated. When
expressed in combination, human Diet1 and FGF19 coimmuno-
precipitated, as did mouse Diet1 and FGF15 (Figure 6D, top
panels, starred bands). The conservation of this interaction
with both human and mouse proteins is significant given thatCthe FGF19 and FGF15 proteins diverge substantially in their pri-
mary amino acid sequence (approximately 50% identity) (Wright
et al., 2004). Precipitations were specific, as shown by lack of
precipitation with IgG or with unrelated proteins carrying the
same epitope tags (Kdm5c-V5 and FABP6-Myc) (Figure 6D, con-
trol panels). The direct effect of Diet1 on FGF19 protein (Figures
5E and 5F) and the subcellular colocalization and protein-protein
interactions between Diet1 and FGF15/19, suggest that impair-
ment of this interaction in Diet1 deficiency contributes to the
reduced FGF15/19 levels observed.
DISCUSSION
Spontaneous mutations in mice and humans have been valuable
tools for the discovery of critical protein functions in metabolism.
We capitalized on a spontaneous mutation that occurred in the
C57BL/6ByJ mouse strain to identifyDiet1. We previously deter-
mined that B6By mice have elevated bile acid levels and sub-
stantial bile acid excretion in the urine and feces (Phan et al.,
2002). They also have reduced plasma lipid levels compared to
C57BL/6J mice, and we proposed that the enhanced conversion
of cholesterol to bile acids, followed by excretion constitutes a
means for reducing circulating cholesterol levels (Mouzeyan
et al., 2000; Phan et al., 2002). However, without knowing the ge-
netic lesion underlying this phenotype, we were unable to deter-
mine the physiological mechanism for the increased bile acidell Metabolism 17, 916–928, June 4, 2013 ª2013 Elsevier Inc. 923
Figure 6. Diet1 and FGF15/FGF19 Proteins
Interact
(A) Subcellular localization of Diet1 and FGF15
proteins overlap in rat intestinal cells. Immunoflu-
orescence confocal microscopy was performed
on IEC-6 rat intestinal cells expressing V5-tagged
Diet1 and untagged mouse FGF15.
(B) Higher magnification of an IEC-6 cell stained
for Diet1 and FGf15 proteins. Several sites of Diet1
and FGF15 colocalization were observed (white
arrowheads), which can be appreciated by com-
parison of single channel black-and-white images
to visualize dots with common positions and by
merging of images (right panel).
(C) Diet1 failed to colocalize with markers of early
endosomes (EEA1 and Rab5), late endosomes
(Rab7), or lysosomes (LimpII) in IEC-6 cells.
(D) Coimmunoprecipitation of Diet1 and FGF15/
FGF19. HumanHEK293T cells were cotransfected
with human Diet1-V5 and FGF19-Myc, mouse
Diet1-V5 and FGF15-Myc, or controls including
empty vectors and vectors expressing irrelevant
proteins (Kdm5c-V5 and FABP6-Myc). Interaction
was observed only when human Diet1 and FGF19,
or mouse Diet1 and FGF15, were cotransfected
(indicated by asterisks in the top panels). The
interaction occurred in both directions, e.g., when
Diet1 was pulled down with the V5 antibody and
when FGF19/FGF15 was pulled down with the
Myc antibody. Diet1 and FGF19 did not coimmu-
noprecipitate with irrelevant proteins (Fabp6 or
Kdm5c) carrying the V5 and Myc epitope tags.
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Diet1 in the Enterohepatic Signaling Axissynthesis. Here we demonstrate that B6By mice carry a null mu-
tation in the geneDiet1. Diet1 has a role in the FGF15/19 axis that
serves to communicate between intestine and liver to regulate
hepatic bile acid synthesis (Figure 7). Loss of Diet1 function leads
to reduced FGF15 levels, impaired feedback regulation of
Cyp7a1, and subsequent dysregulated bile acid synthesis
(Figure 7).
Our conclusion that Diet1 levels in the small intestine influence
hepatic bile acid metabolism through effects on FGF15/19 is
based on several observations. First, Diet1 deficiency led to
reduced Fgf15mRNA and protein levels in ileum, and restoration
of very low levels of Diet1 expression by transgenesis caused
increased Fgf15 expression levels in B6By intestine. Further-
more, variations in the level of Diet1 expression were correlated
with intestinal Fgf15 expression levels and negatively correlated
with hepatic Cyp7a expression levels. Second, introduction of
FGF15 into Diet1-deficient mice via adenoviral-mediated
expression led to a dramatic reduction in Cyp7a1 levels, indi-924 Cell Metabolism 17, 916–928, June 4, 2013 ª2013 Elsevier Inc.cating that the lack of FGF15 is a key
component of the effects of Diet1 defi-
ciency. Third, acute changes in Diet1
expression levels in a human intestinal
cell line modulated FGF19 production:
Diet1 overexpression increased, and
Diet1 knockdown reduced, the amount
of secreted FGF19. And fourth, Diet1
and FGF15/19 proteins showed evidence
of a physical interaction. Specifically,Diet1 and FGF15 exhibited an overlapping subcellular distribu-
tion in vesicle-like structures, and Diet1 and FGF19 proteins
coimmunoprecipitated in a complex. Together, these data
demonstrate that Diet1 and FGF15/19 are associated both func-
tionally and physically.
A key prediction of our model shown in Figure 7 is that Diet1-
deficient mice should resemble genetically engineeredmice with
reduced FGF15 levels or enhanced Cyp7a1 expression. This is
indeed the case. Diet1-deficient mice exhibit increased bile
acid excretion and elevated hepatic Cyp7a1 expression, as
observed in Fgf15 knockout mice (Inagaki et al., 2005); elevated
bile acid levels in intestine, gall bladder, and feces; and resis-
tance to diet-induced hyperlipidemia, as seen in Cyp7a1 trans-
genic mice (Li et al., 2011; Li et al., 2010). However, in contrast
to the increased intestinal Fgf15 expression that occurs in
Cyp7a1 transgenic mice, Diet1-deficient mice have reduced
Fgf15 mRNA levels, consistent with a role for Diet1 in attaining
optimal FGF15 levels. Fgf15 gene expression is regulated by
Figure 7. Proposed Role of Diet1 in Entero-
hepatic Signaling for Regulation of Bile Acid
Homeostasis
In wild-type animals, Diet1 levels in the small in-
testine are correlatedwith levels of FGF15 in ileum,
which influence feedback regulation of hepatic
Cyp7a1 expression and the resulting bile acid
levels. In Diet1-deficient mice, FGF15 levels are
diminished and feedback regulation of hepatic bile
acid synthesis is impaired, leading to increased
bile acid levels in the gastrointestinal tract and
circulation.
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Diet1 in the Enterohepatic Signaling AxisFXRa, and intestine-specific FXRa deficiency results in reduced
Fgf15 gene expression despite a modestly increased bile acid
pool size (Kim et al., 2007). This raises the question of whether
Diet1 deficiency reduces Fgf15 expression via an FXRa-medi-
atedmechanism.Our data suggest that this is not the case, since
Diet1-deficient mice express several FXRa target genes at
normal levels in liver (Nr0b2 and Abcb11) and ileum (Nr0b2,
Fabp6, Osta, and Ostb).
Our data indicate that Diet1 influences FGF15/19 levels via
transcriptional and posttranscriptional mechanisms. Diet1 and
FGF15/19 proteins colocalize and coimmunoprecipitate, pro-
viding additional evidence for posttranslational interaction. In
mouse intestine and cultured intestinal-derived epithelial cells,
Diet1 appears in a punctate cytosolic distribution, reminiscent
of endotubin, the protein with strongest sequence similarity to
Diet1 (Wilson and Colton, 1997). Both Diet1 and endotubin are
composed of modular repeating MAM and LDL receptor
domains, and each possesses a single predicted membrane-
spanning domain at the C terminus, which may localize these
proteins to endosomal or other vesicular compartments.
Recent work suggests that endotubin regulates trafficking of
polarity proteins and tight-junction components out of the
endosomal compartment, a process that occurs in developing
epithelial cells to establish polarity (McCarter et al., 2010).
Diet1 is distributed throughout the cytosol in contrast to endo-
tubin, which is restricted to the subapical region. This suggests
that Diet1 and endotubin reside in distinct endosomal popula-
tions. Our failure to detect Diet1 colocalization with standard
early-endosomal, late-endosomal, or lysosomal markers sug-
gests that it may inhabit a specialized endosomal com-
partment. A proportion of FGF15 colocalized with Diet1,
suggesting a potential role for Diet1 in its intracellular transport
itinerary.
Recent studies in humans have shown important relationships
between FGF19 levels, bile acid synthetic rates, and intestinal
disorders (reviewed in Angelin et al., 2012). It has been known
for decades that elevated bile acid levels occur in Crohn’s dis-Cell Metabolism 17, 916–ease, congenital diarrhea, postinfectious
diarrhea, short bowel syndrome, and dis-
orders classified as idiopathic diarrhea or
bile acid malabsorption syndromes (Wal-
ters and Pattni, 2010). Recently, it has
been proposed that the elevated bile
acid levels in many, and perhaps most,
of these conditions are not a result ofimpaired bile acid absorption in the intestine, but rather to
increased hepatic bile acid synthesis due to impaired negative
feedback regulation (Hofmann, 2009; Johnston et al., 2011; Wal-
ters and Pattni, 2010). Walters and colleagues demonstrated a
central role for low levels of FGF19 in bile acid diarrhea (Walters
et al., 2009). In subjects with chronic diarrhea, FGF19 levels were
reduced and were negatively correlated with serum 7a-hydroxy-
4-cholesten-3-one (C4), a precursor of bile acids and marker for
bile acid synthetic rate. Furthermore, in a study of more than 400
healthy individuals, there were large interindividual variations in
bile acid synthesis levels as inferred by C4 measurements, and
C4 levels were negatively correlated with FGF19 levels (Ga¨lman
et al., 2011).
The findings described above suggest that interindividual var-
iations in bile acid levels, as well as pathogenic elevations in bile
acid levels observed in disease, may reflect variations in FGF19
levels. Therapeutic strategies that modulate FGF19 levels may
be warranted. In the case of chronic bile acid diarrhea syn-
dromes (previously called bile acid malabsorption syndromes),
strategies to elevate FGF19 to normal levels would be desirable.
On the other hand, individuals with hyperlipidemia may benefit
from promoting bile acid synthesis. This has historically been
achieved by treatment with bile acid sequestrants, which have
recently received attention as a potential means to reduce
both hyperlipidemia and hyperglycemia (Aggarwal et al., 2012;
Handelsman 2011; Out et al., 2012). Problems remain with bile
acid sequestrants, however, in their low palatability and long-
term adherence rates. The modulation of FGF19 levels up or
down thus appears to be an attractive alternative therapeutic
strategy for bile acid overproduction syndromes and hyperlipid-
emia, respectively. Fgf15/19 gene transcription is regulated by
bile acids through FXRa, and by vitamins D and A (Schmidt
et al., 2010). Diet1 levels appear to be an additional control point
for FGF15/19 levels, with potential effects at the transcriptional
and posttranscriptional levels. At present, it is unknown what
regulates Diet1 expression; preliminary studies in our laboratory
indicate that neither bile acids nor agonists for FXR or several928, June 4, 2013 ª2013 Elsevier Inc. 925
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Diet1 in the Enterohepatic Signaling Axisother nuclear receptors have significant effects, and this will
require further investigation. Further investigation into the mech-
anism by which Diet1 protein influences FGF15/19 levels at the
posttranscriptional level is also warranted. The subcellular co-
localization and coimmunoprecipitation of the two proteins raise
several possibilities, including effects on FGF15/19 protein sta-
bility, intracellular trafficking, or secretion.
Finally, our findings raise the possibility that common genetic
variations in DIET1 may influence bile acid and lipid levels in the
general population and that rare mutations may underlie condi-
tions characterized by low FGF19 levels, including bile acid
malabsorption syndromes. An examination of data from recent
genome-wide association studies (Aulchenko et al., 2009; Chas-
man et al., 2009; Kathiresan et al., 2009; Sandhu et al., 2008;
Teslovich et al., 2010) has not revealed genome-wide significant
associations between the interval on chromosome 10p12 that
harbors theDIET1 gene and lipid levels in the general population.
This is not unexpected, sincewe predict that genetic variations in
DIET1 should influence lipid levels indirectly through an effect on
bile acid synthesis and feedback regulation and thus would best
be detected in individuals with hyperlipidemia in conjunctionwith
low bile acid levels. A better evaluation of whether common
variations inDIET1 have effects on lipid levels awaits the analysis
of a large study sample in which bile acid levels are available.
Future studies will also address whether rare mutations in
DIET1 may underlie conditions characterized by high bile acid
and low FGF19 levels, as described in some cases of idiopathic
bile acid malabsorption (Walters et al., 2009).
EXPERIMENTAL PROCEDURES
Diet1 Genetic Mapping
C57BL/6ByJ, C57BL/6J, and CAST/EiJ mice were obtained from The Jackson
Laboratory (Bar Harbor, ME). Mouse studies were conducted in accordance
with, and approved by, the Institutional Animal Research Committee of the
University of California, Los Angeles. For high-resolution genetic mapping of
theDiet1 gene, C57BL/6ByJmice were crossedwith CAST/EiJ, and the result-
ing F1 animals were backcrossed to C57BL/6ByJ. Mice were genotyped with
DNA microsatellite markers and at 2 months of age were fed the atherogenic
diet (7.5% cocoa butter, 1.25% cholesterol, 0.5% sodium cholate; TD90221,
Teklad Research Diets, Madison, WI) for 3 weeks. Bile acid levels were deter-
mined as done previously (Phan et al., 2002). Sequencing of the wild-type and
mutant Diet1 genes was performed as described in the Supplemental Exper-
imental Procedures.
Diet1 Transgenic Mice
Diet1 transgenic (Diet1-Tg) mice were produced by cloning of C57BL/6J
mouse Diet1 cDNA downstream of the regulatory sequences of the rat intes-
tinal fatty acid binding protein (1178 to +28), which direct expression to small
intestine (Cohn et al., 1992), and upstream of a C-terminal V5 epitope tag and
an SV40 intron/poly(A) sequence. Microinjection into fertilized mouse C57BL/
6J oocytes was performed to establish a transgenic line. Expression of the
transgene was distinguished from endogenous Diet1 using PCR primers that
span the Diet1-V5 junction and antibodies directed against V5 (Bethyl Labora-
tories, Montgomery, TX). For rescue of Diet1 expression in B6By mice, trans-
genic mice were crossed to B6By, and F1 progeny were backcrossed to B6By
mice. Nontransgenic mice homozygous for the B6By Diet1 null allele (no
endogenous Diet1) were compared with littermates that were homozygous
for the B6By Diet1 allele and hemizygous for the Diet1-V5 transgene.
Diet1 Expression and Knockdown
The coding sequences of human DIET1 were amplified by PCR without the
stop codon and were cloned into the pcDNA3.1-V5/His-TOPO TA expression926 Cell Metabolism 17, 916–928, June 4, 2013 ª2013 Elsevier Inc.vector (Invitrogen) to obtain the V5/His epitope tag in frame with the Diet1 pro-
tein. Human intestinal cell line HT-29 was transfected with either empty vector
or DIET1-V5 with BioT transfection reagent (Bioland). Knockdown studies
were performed with a pool of three custom Stealth siRNAs (Invitrogen)
(50-CAGCCCAAUCCUUAAUGCCACUGAU-30, 50-CAGACAGGACCUGGAU
GCAUACUUU-30, and 50-GAGUUGCAGAUAGUUACCAAUAGUA-30) trans-
fected into cells with Lipofectamine RNAiMAX (Invitrogen). As a control, cells
were transfected with scrambled siRNA (50-UCCAACCAGUGGGUGAAACU
GUUAA-30). Forty-eight hours after transfection, culturemediumwas collected
for protein quantitation, and cells were collected for RNA isolation. FGF19 and
apolipoprotein AI protein levels were determined in the culture medium using
an FGF19 ELISA immunoassay (R & D Systems) and Human Apolipoprotein AI
ELISApro (Mabtech), respectively. For studies of Diet1 effects on FGF19 at the
posttranscriptional level, FGF19 was expressed under the control of a heterol-
ogous promoter in the pcDNA6/Myc-His expression vector (Invitrogen). Levels
of cellular Diet1 and FGF19 protein and secreted FGF19 protein were as-
sessed by western blot analysis and were quantified with ImageJ software.
Additional Methods
Complete descriptions of Diet1 sequencing, Southern and northern blot ana-
lyses, in situ hybridization, immunohistochemistry and immunofluorescence,
coimmunoprecipitation studies, and PCR primer sequences are provided in
Supplemental Experimental Procedures.
ACCESSION NUMBERS
Sequences forDiet1mRNA from the following species have been deposited in
GenBank: mouse, KC836882; human, KC843478; rat, KC845479; chicken,
KC843480; Xenopus tropicalis, KC843481; and zebrafish, KC843482.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures, one table, and Supplemental
Experimental Procedures and can be found with this article online at http://
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